BioSpace News Archive

Policy

Seagen CEO Takes Leave of Absence Following Domestic Violence Allegation

Today’s announcement from Seagen’s board of directors included difficult news regarding Clay Siegall, Ph.D. Until today, Siegall served as Seagen’s President, CEO and Chairman.

May 9, 2022
·
2 min read
·
Jazmine Colatriano M.S.
Policy

Moderna Urges Court to Dismiss Ongoing Vaccine Patent Issues

Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.

May 9, 2022
·
3 min read
·
Mark Terry
Career Advice

5 Ways to Make Your Resume Stand Out From the Crowd

According to a survey by CareerBuilder, 23% of hiring managers spend less than 30 seconds reading a resume. Make the most of those seconds with these five tips to make your resume stand out.

May 9, 2022
·
3 min read
·
Editorial Team
Drug Development

BioNTech Forges Ahead in Oncology, Infectious Disease

BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.

May 9, 2022
·
3 min read
·
Alex Keown
Drug Development

Athira Pharma Extends Study Duration for Alzheimer’s Study

Athira Pharma announced the duration of its open-label study of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s Disease (AD) has been increased from six months to eighteen months.

May 9, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

LogicBio Cleared to Continue Dosing in Pediatric MMA Trial

LogicBio Therapeutics has received the green light to continue dosing participants in its Phase I/II Sunrise trial, following a clinical hold placed by the FDA due to adverse events in pediatric patients.

May 9, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
The Rise and Expansion of Cytokine-based Therapy

Some cytokines can stimulate the immune system, while others slow it down. Here’s a look at the latest news on cytokine data and therapy developments.

May 9, 2022
·
4 min read
·
Mark Terry
Drug Development

Oxurion Goes Back to the Drawing Board for DME Treatment

Oxurion NV’s proposed drug for diabetic macular edema failed to demonstrate efficacy on key endpoints based on top line results from its Phase II trial.

May 9, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Orion to Cut 32 Jobs, Focus on Pain and Oncology

Orion announced that it will be focusing on pain and oncology going forward. As a result, 32 working professionals within the company will be terminated, although six of those will be offered different positions.

May 9, 2022
·
2 min read
·
Hayley Shasteen
Business

Aspen Reels in $147.5M to Advance Personalized Parkinson’s Therapy

Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.

May 9, 2022
·
3 min read
·
Mark Terry